ImmunoGen (NASDAQ:IMGN) is scheduled to be posting its quarterly earnings results before the market opens on Friday, February 8th. Analysts expect ImmunoGen to post earnings of ($0.33) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.
IMGN stock opened at $5.49 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.59 and a quick ratio of 4.56. ImmunoGen has a 12 month low of $3.80 and a 12 month high of $13.41. The company has a market capitalization of $720.11 million, a PE ratio of -7.32 and a beta of 2.36.
A number of equities analysts have recently commented on the stock. ValuEngine upgraded shares of ImmunoGen from a “hold” rating to a “buy” rating in a research report on Wednesday, October 17th. William Blair restated an “outperform” rating on shares of ImmunoGen in a research report on Monday, October 22nd. HC Wainwright set a $18.00 price objective on shares of ImmunoGen and gave the company a “buy” rating in a research report on Monday, October 22nd. BidaskClub lowered shares of ImmunoGen from a “hold” rating to a “sell” rating in a research report on Wednesday, October 24th. Finally, Piper Jaffray Companies set a $14.00 price objective on shares of ImmunoGen and gave the company a “buy” rating in a research report on Sunday, December 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the stock. ImmunoGen presently has a consensus rating of “Buy” and an average price target of $14.60.
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Read More: Bear Market – How and Why They Occur
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.